🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

PRESS DIGEST- Financial Times - Dec 19

Published 2016-12-18, 08:28 p/m
© Reuters.  PRESS DIGEST- Financial Times - Dec 19
SCAb
-
AAPL
-
Praxair Inc
-
AMRX
-

Dec 19 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

* Dublin claims Brussels exceeded powers over Apple tax http://on.ft.com/2hXjsyS

* Sweden's SCA nears 2.7 bln euro deal to buy Germany's BSN Medical http://on.ft.com/2hXlHCa

* Praxair (NYSE:PX) and Linde close in on $65 bln deal http://on.ft.com/2hXlEqf

* US drugmaker charges 200 times UK price for common worm pill http://on.ft.com/2hXtZKf

Overview

- Ireland laid out grounds for its appeal against the European Commission's demand that it claw back 13 billion euros of state aid from Apple AAPL.O . It accused Brussels of interfering with national sovereignty.

- Personal care-to-forestry products group SCA SCAb.ST , is nearing a deal to buy German bandage maker BSN Medical for 2.7 billion euros including debt, ahead of a plan to separate into two publicly traded parts next year.

- Praxair PX.N , the US industrial group, and Germany's Linde are set to announce preliminary terms of their $65 billion merger as early as Wednesday in a deal that will create the world's largest supplier of industrial gas.

- Impax Laboratories IPXL.O put a price tag of more than $800 on a pinworm treatment - 200 times more expensive than the equivalent medicine on British pharmacy shelves.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.